GenomeDx Biosciences and Astellas announced a collaboration to apply genomic tumor profiling using GenomeDx’s Decipher Classifier and Decipher GRID as a potential aid in identifying prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide (Xtandi).
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
